A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen

Geremia B. Bolli MD1 | Carol Wysham MD2 | Miles Fisher MD3 | Soazig Chevalier MS4 | Anna M. G. Cali MD4 | Bruno Leroy MD4 | Matthew C. Riddle MD5

1Department of Medicine, University of Perugia, Perugia, Italy
2Diabetes and Endocrinology Center, Rockwood Clinic, Spokane, Washington
3Glasgow Royal Infirmary, University of Glasgow, Glasgow, UK
4Sanofi, Paris, France
5Oregon Health and Science University, Portland, Oregon

Correspondence
Geremia B. Bolli, MD, Section of Endocrinology and Metabolism, Department of Medicine, Hospital S.M. della Misericordia, Piazzale Gambuli, 1, 06129 Perugia PG, Italy. Email: geremia.bolli@unipg.it

Funding information
These analyses and the clinical trials providing the data analysed (NCT01499095, NCT01676220, NCT01689142) were sponsored by Sanofi.

The EDITION trials in type 2 diabetes demonstrated comparable glycaemic control with less nocturnal and anytime (24-hour) hypoglycaemia for insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100). However, the predefined nocturnal window (0:00–5:59 AM) may not be the most relevant for clinical practice. This post-hoc analysis compared expansions of the predefined nocturnal interval during basal insulin treatment without prandial insulin. Patient-level, 6-month data, pooled from the EDITION 2 and 3 trials and the EDITION JP 2 trial (N = 1922, basal insulin only) were analysed. Accompanying hypoglycaemia during treatment with Gla-300 was compared to that during treatment with Gla-100, using predefined (0:00–5:59 AM) and expanded (10:00 PM–5:59 AM, 0:00–7:59 AM, 10:00 PM to pre-breakfast SMPG) windows. Confirmed (&lt;3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemic events were reported most frequently between 6:00 AM and 8:00 AM. Windows expanded beyond 6:00 AM included more events than other windows. The percentage of participants with at least one event was lower with Gla-300 than Gla-100 in all windows examined. Expanding the nocturnal interval allows better assessment of the risk of hypoglycaemia associated with basal insulin. The risk of nocturnal hypoglycaemia was consistently lower with Gla-300 versus Gla-100 using all four windows.

KEYWORDS
basal insulin, hypoglycaemia, type 2 diabetes

1 INTRODUCTION
Basal insulin is an essential component of the management strategy for individuals with type 2 diabetes (T2DM), and is often required when lifestyle interventions and non-insulin glucose-lowering agents fail to achieve target glycaemic control. However, basal insulin treatment is often delayed, and/or dose titration is not optimized, resulting in poor glucose control despite initiation of insulin. Studies have identified fear of hypoglycaemia as one of the dominant reasons for suboptimal use of basal insulin. Hypoglycaemic events often occur at night, when warning symptoms are physiologically blunted, and may result in both acute and long-term clinical consequences. As such, these nocturnal events elicit fear, in both the individuals with T2DM and the healthcare practitioners. Long-acting basal insulin analogues have been developed to deliver constant and predictable glucose-lowering effects over 24 hours, providing improved glycaemic control and reduced risk of nocturnal hypoglycaemia because of a rather flat pharmacodynamic (PD) profile.

Insulin glargine 300 U/mL (Gla-300) has more stable and prolonged pharmacokinetic (PK) and PD profiles than insulin glargine 100 U/mL (Gla-100). The EDITION treat-to-target clinical trials showed that the improved PK and PD properties of Gla-300 translate...
into clinical benefits such as glycaemic control equivalent to that of Glia-100 with less hypoglycaemia in individuals with T2DM, primarily, but not exclusively, at night (defined as 00:00–05:59 AM).6–8

The value of extending time intervals beyond 00:00–5:59 AM when assessing nocturnal hypoglycaemia has been shown in a patient-level meta-analysis of the global EDITION trials in T2DM (EDITION 1, 2 and 3), in which a clinically defined window from 10:00 PM to the time of pre-breakfast self-monitored plasma glucose (SMPG) measurement (median, 7:30 AM) resulted in the inclusion of many more hypoglycaemic events compared to the predefined 0:00–5:59 AM window, and confirmed a clinically relevant reduction in the risk of hypoglycaemia with Glia-300 during the overnight fasting period.9 However, the EDITION 1 trial7 examined individuals using prandial insulin in addition to basal insulin; thus, the results may not be specifically attributed to basal insulin alone.

The present post-hoc analysis was designed to evaluate the risk of nocturnal hypoglycaemia with Glia-300 vs Glia-100 by using data pooled from three trials in which participants with T2DM used only basal insulin (EDITION 2, 3 and JP 2) without the confounding effects of the prandial insulin used in EDITION 1. Hypoglycaemia at night was analysed using the predefined 0:00–5:59 AM nocturnal interval and three expansions thereof.

2 METHODS

2.1 Trial design

EDITION 2, EDITION 3 and EDITION JP 2 were multicentre, randomized, open-label, two-arm, parallel-group, phase 3a studies in different populations of adults with T2DM (NCT01499095, NCT01676220, NCT01689142) and have been described previously.6,8,10 In EDITION 2 populations of adults with T2DM (NCT01499095, NCT01676220, all trials had a similar design, and the consistent study designs and endpoints allowed a pooled analysis. Hypoglycaemia over 6 months was assessed in safety populations by analysing patient-level data pooled from the EDITION 2, 3 and JP 2 trials. Point estimates for the relative risk and 95% confidence intervals (CIs) for the percentage of participants with at least one hypoglycaemic event were estimated using the Cochran–Mantel–Haenszel method, while rates of hypoglycaemia (events per participant-year) were analysed using an over-dispersed Poisson regression model to determine rate ratios and 95% CIs.

3 RESULTS

Baseline characteristics (Table S1) were, in general, similar between the trials, with the exception of BMI, which was lower in the EDITION JP 2 trial (mean [SD]: Glia-300, 25.7 [4.0]; Glia-100, 24.8 [3.6] kg/m²) than in the EDITION 2 trial (mean [SD]: Glia-300, 34.8 [6.6]; Glia-100, 34.8 [6.1] kg/m²) and the EDITION 3 trial (mean [SD]: Glia-300, 32.8 [6.9]; Glia-100, 33.2 [6.6] kg/m²). Distribution, by time of day, of the time of the pre-breakfast SMPG and basal insulin injection was
using windows that extended past 6:00 AM (Table 1). A greater percentage of 24-hour events were defined as nocturnal when severe hypoglycaemia (Figure 1B) a similar pattern was observed. A comparable result was found when using nocturnal window definitions that extended past 5:59 AM (Figure S2). For confirmed (<3.0 mmol/L [<54 mg/dL]) or severe hypoglycaemia event at both the (A) ≤ 3.9 mmol/L [<70 mg/dL] threshold and the (B) ≤ 3.0 mmol/L [<54 mg/dL] threshold (safety population) – Pool of results from the EDITION 2, EDITION 3 and EDITION JP 2 trials. Gla-300 N = 958, Gla-100 N = 964. Abbreviation SMPG, self-monitored plasma glucose.

FIGURE 1 Percentage of participants with at least one confirmed or severe hypoglycaemic event at both the (A) ≤ 3.9 mmol/L [<70 mg/dL] threshold and the (B) ≤ 3.0 mmol/L [<54 mg/dL] threshold (safety population) – Pool of results from the EDITION 2, EDITION 3 and EDITION JP 2 trials. Gla-300 N = 958, Gla-100 N = 964. Abbreviation SMPG, self-monitored plasma glucose.

At every time point analysed, fewer participants reported confirmed (≤3.9 mmol/L [<70 mg/dL]) or severe hypoglycaemia with Gla-300 than with Gla-100 (Figure 1A). This finding was consistent with those of the individual EDITION 2, 3 and JP 2 trials, in which, for the majority of time points, fewer participants reported confirmed (≤3.9 mmol/L [<70 mg/dL]) or severe hypoglycaemia with Gla-300 than with Gla-100 (Figure S2). For confirmed (≤3.0 mmol/L [<54 mg/dL]) or severe hypoglycaemia (Figure 1B) a similar pattern was observed. A greater percentage of 24-hour events were defined as nocturnal when using windows that extended past 6:00 AM (Table 1).

Percentage of participants with ≥ one confirmed (≤3.9 mmol/L [<70 mg/dL]) or severe hypoglycaemic event almost doubled when using nocturnal window definitions that extended past 5:59 AM (0:00–7:59 AM and 10:00 PM to pre-breakfast SMPG) vs the predefined window (0:00–5:59 AM) (Table 1). This was consistent with results from the individual EDITION trials (S2). The risk of at least one confirmed (≤3.9 mmol/L [<70 mg/dL]) or severe event was consistently lower with Gla-300 than with Gla-100, regardless of the nocturnal window used (Figure S3). Approximately two to three times more hypoglycaemic events were identified during nocturnal windows that extended past 5:59 AM vs the predefined window in the pooled analyses (Table 1), consistent with results from the individual EDITION 2, 3 and JP 2 trials (Table S2). Annualized rates of hypoglycaemia also increased approximately two-fold when using extended nocturnal windows, for all definitions of hypoglycaemia (Table 1 and S4).

4 | DISCUSSION

The aim of this post-hoc study was to more fully explore the 24-hour time course and the clinical significance of hypoglycaemic events occurring during treatment of T2DM with basal insulin only by comparing the risk of hypoglycaemia during the predefined nocturnal window commonly used in clinical trials with expanded windows.

This analysis of pooled, patient-level data from the EDITION 2, 3 and JP 2 studies demonstrates that the incidence of reported hypoglycaemia with both Gla-300 and Gla-100 was highest during the 6:00–8:00 AM interval, outside the standard, predefined 0:00–5:59 AM window. The number of hypoglycaemic events reported was more than doubled by including this 2-hour period, suggesting that a window incorporating this time interval is of clinical relevance when examining the role of basal insulin. The pattern of findings from pooled data was also seen in the individual EDITION studies. The high number of events during the 6:00–8:00 AM interval may be related to the protocol-mandated measurement of pre-breakfast SMPG, but the fact that this interval, which is approximately 8–11 hours after basal insulin injection, near dawn and often before the first meal of the day, includes more events is compatible with the pharmacodynamics of basal insulin in T2DM during nocturnal fasting.13 In clinical reality, up-titration of basal insulin would increase the dose until the dawn phenomenon was overcome, and euglycaemia would ideally be achieved without risk of hypoglycaemia.

Lower risk of hypoglycaemia with Gla-300 vs Gla-100 extends past the predefined nocturnal window (0:00–5:59 AM), in line with the flatter and more evenly distributed PK and PD profiles of Gla-300 compared with Gla-100. The observation in the present study of a higher risk of hypoglycaemia during waking hours may not inspire the fear of events that occur during sleep; however, these events are still important and clinically relevant, and efforts should be made to minimize the frequency of their occurrence.

Recently, a comparable analysis using pooled data from three trials of Gla-300 (EDITION 1, 2 and 3) in T2DM was reported,9 with results similar to those presented here, including the finding that, while the relative risk and rate ratios move closer to 1.00 with the extended intervals, the conclusion of a reduced risk of hypoglycaemia with Gla-300 vs Gla-100 remains. However, only the present study indicates that the peak of hypoglycaemia incidence at 6:00–8:00 AM is specifically the result of basal insulin, as, in the previous study,9 the prandial insulin at breakfast in the EDITION 1 trial might have confounded the risk of hypoglycaemia occurring almost 12 hours after evening injection of Gla-300 or Gla-100. Together, the previous study9 and the current, more specific, analysis provide strong evidence that evening injections of basal insulin confer the greatest risk of hypoglycaemia during the 6:00–8:00 AM time interval.

Interestingly, the results observed in the EDITION JP 2 trial, which investigated Japanese participants, were similar to those
| Nocturnal window | 0:00–5:59 AM (predefined window in EDITION studies) | 10:00 PM–5:59 AM | 0:00–7:59 AM | 10:00 PM to pre-breakfast SMPG |
|-----------------|---------------------------------|-----------------|-----------------|------------------|
|                 | Gla-300 (N = 958) | Gla-100 (N = 964) | Difference | Gla-300 (N = 958) | Gla-100 (N = 964) | Difference | Gla-300 (N = 958) | Gla-100 (N = 964) | Difference | Gla-300 (N = 958) | Gla-100 (N = 964) | Difference |
| Confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe | | | | | | | | | | | | |
| Participants with ≥1 hypoglycaemic event (%) | 23.6 | 33.2 | 9.6 | 28.6 | 36.6 | 8.0 | 40.9 | 52.4 | 11.5 | 44.9 | 57.1 | 12.2 |
| Total number of events | 754 | 1275 | 521 | 925 | 1412 | 487 | 2173 | 3132 | 959 | 2260 | 3210 | 950 |
| Events per participant, y | 1.7 | 2.8 | 1.1 | 2.1 | 3.1 | 1.0 | 4.8 | 6.9 | 2.1 | 5.0 | 7.1 | 2.1 |
| Percentage of events in 24 h defined as nocturnal | 16.4 | 20.6 | 4.2 | 20.2 | 22.8 | 2.6 | 47.4 | 50.7 | 3.3 | 49.3 | 51.9 | 2.6 |
| Confirmed (<3.0 mmol/L [<54 mg/dL]) or severe | | | | | | | | | | | | |
| Participants with ≥1 hypoglycaemic event (%) | 7.2 | 10.0 | 2.8 | 8.6 | 11.7 | 3.1 | 10.4 | 14.7 | 4.3 | 12.2 | 17.0 | 4.8 |
| Total number of events | 112 | 191 | 79 | 140 | 214 | 74 | 209 | 317 | 108 | 251 | 357 | 106 |
| Events per participant, y | 0.3 | 0.4 | 0.1 | 0.3 | 0.5 | 0.2 | 0.5 | 0.7 | 0.2 | 0.6 | 0.8 | 0.2 |
| Percentage of events in 24 h defined as nocturnal | 26.0 | 34.2 | 8.2 | 32.6 | 38.4 | 5.8 | 48.6 | 56.8 | 8.2 | 58.4 | 64.0 | 5.6 |
| Documented symptomatic (≤3.9 mmol/L [≤70 mg/dL]) | | | | | | | | | | | | |
| Participants with ≥1 hypoglycaemic event (%) | 17.1 | 23.4 | 6.3 | 19.9 | 25.7 | 5.8 | 26.4 | 33.1 | 6.7 | 29.3 | 35.9 | 6.6 |
| Total number of events | 468 | 721 | 253 | 529 | 782 | 253 | 1029 | 1351 | 322 | 1075 | 1445 | 370 |
| Events per participant, y | 1.0 | 1.6 | 0.6 | 1.2 | 1.7 | 0.5 | 2.3 | 3.0 | 0.7 | 2.4 | 3.2 | 0.8 |
| Percentage of events in 24 h defined as nocturnal | 23.1 | 28.1 | 5.0 | 26.2 | 30.4 | 4.2 | 50.9 | 52.6 | 1.7 | 53.2 | 56.2 | 3.0 |
| Documented symptomatic (<3.0 mmol/L [<54 mg/dL]) | | | | | | | | | | | | |
| Participants with ≥1 hypoglycaemic event (%) | 5.8 | 8.6 | 2.8 | 6.8 | 9.6 | 2.8 | 8.2 | 11.4 | 3.2 | 9.6 | 13.2 | 3.6 |
| Total number of events | 83 | 162 | 79 | 100 | 177 | 77 | 138 | 239 | 101 | 178 | 272 | 94 |
| Events per participant, y | 0.2 | 0.4 | 0.2 | 0.2 | 0.4 | 0.2 | 0.3 | 0.5 | 0.2 | 0.4 | 0.6 | 0.3 |
| Percentage of events in 24 h defined as nocturnal | 28.8 | 41.4 | 12.6 | 34.7 | 45.3 | 10.6 | 47.9 | 61.1 | 13.2 | 61.8 | 69.6 | 7.8 |

Abbreviation: SMPG, self-monitored plasma glucose.
Difference, Gla-100 minus Gla-300 (please also see Figures S3 and S4 for results of specific analysis of the differences between Gla-300 and Gla-100, including relative risks, rate ratios and associated confidence intervals).
observed in the EDITION 2 and 3 trials, which investigated Western populations, despite lower BMI and lower doses of insulin in the EDITION JP 2 trial. In theory, the use of sulphonylureas and/or glinides in the EDITION JP 2 trial might have confounded the results of the present pooled analysis, as sulphonylureas increase the risk of hypoglycaemia and were not allowed in the EDITION 2 and 3 trials. However, such confounding seems unlikely because a similar percentage of participants using sulphonylureas and/or glinides were allocated to the Gla-300 and Gla-100 groups in the EDITION JP 2 trial, and because the 24-hour distribution of hypoglycaemia in the EDITION JP 2 trial was similar to that seen in the EDITION 2 and 3 trials. Thus, inclusion of the EDITION JP 2 trial, which is representative of an Asian population, enriches and strengthens the present pooled analysis of the 24-hour distribution of hypoglycaemia.

A similar study analysing rates of nocturnal hypoglycaemia with insulin degludec vs Gla-100 also demonstrated that adding 2 hours to the conventional, predefined 0:00–5:59 AM nocturnal window resulted in a two- to three-fold increase, with both insulins, in the number of hypoglycaemic episodes per 100 patient-years of exposure. These results highlight contrasts between nocturnal hypoglycaemia, as defined for regulatory submission, and wider definitions which appear to be of more clinical relevance. Use of a wider window may be particularly relevant in examining the risk of hypoglycaemia that is specifically the result of basal insulin in individuals with diabetes, especially in those with a higher risk of hypoglycaemia. In the recently published clinical trial of Gla-300 vs Gla-100 in older individuals with T2DM, the SENIOR study, intervals of 10:00 PM–8:59 AM and 0:00–5:59 AM were both used to categorize nocturnal hypoglycaemia, although only data for the latter interval were reported.

Limitations of the present study include the potential under-reporting of nocturnal events that do not awaken the individual. Use of continuous glucose monitoring devices for future studies would provide a more accurate description of the number and timing of hypoglycaemic events. In addition, the pooled analyses presented here were not pre-specified. However, the EDITION studies were designed from the outset with consistent study designs and endpoints that allowed analysis of pooled data.

In conclusion, this study has demonstrated that hypoglycaemic events that are specifically induced by basal insulin are most frequently reported between 6:00 and 8:00 AM, with the time of breakfast being varied, but most often between 7:00 and 8:00 AM. Broader windows of observation for hypoglycaemia during a nocturnal/fasting period that extends beyond 6:00 AM allow identification of more affected individuals and more events induced by basal insulin. It would be useful if future studies comparing basal insulins could report results of hypoglycaemic events that occurred within this wider window as well as the predefined window. The lower incidence and rate of nocturnal hypoglycaemia with Gla-300 vs Gla-100 was confirmed using all analysed time windows, showing a consistently reduced risk with Gla-300 compared to Gla-100.

ACKNOWLEDGMENTS
The authors thank the study participants, trial staff and investigators for their participation. Editorial and writing assistance was provided by Kerry Knight, PhD of Fishawack Communications Ltd and was funded by Sanofi.

Conflict of interests
G. B. B. is a consultant to Menarini and Sanofi; has provided research support to Sanofi; and is a member of the speakers bureau for Menarini and Sanofi. C. W. serves on advisory panels for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Novo Nordisk and Sanofi; is a consultant to AstraZeneca, Eli Lilly, Janssen and Sanofi; and is a member of the speakers bureau for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Insulet, Janssen, Novo Nordisk and Sanofi. M. F. serves on advisory panels for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Mylan, NAPP, Novo Nordisk, Sanofi and Servier; and is a member of the speakers bureau for MSD. S. C. is an employee of and a stock/shareholder in Sanofi. A. M. G. C. is a consultant to AstraZeneca, Biodel, Elcelyx, GlaxoSmithKline, Sanofi and Valeritas; and has provided research support to AstraZeneca, Eli Lilly, Novo Nordisk and Sanofi.

Author contributions
Sanofi was the sponsor of the studies analysed and was responsible for the design and coordination of the trials, the monitoring of clinical sites, the collection and management of data and the performance of all statistical analyses. G. B. B., A. M. G. C., S. C. and M. C. R. developed the initial concept for this analysis. G. B. B., C. W., M. F., S. C., A. M. G. C., B. L. and M. C. R. participated in interpreting the findings as well as writing, reviewing and editing the manuscript. All authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

ORCID
Geremia B. Bolli https://orcid.org/0000-0003-4966-4003
Matthew C. Riddle https://orcid.org/0000-0003-1169-3036

REFERENCES
1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–1379.
2. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study. Diabet Med. 2012;29:682–689.
3. Edelman SV, Blose JS. The impact of nocturnal hypoglycemia on clinical and cost-related issues in patients with type 1 and type 2 diabetes. Diabetes Educ. 2014;40:269–279.
4. Pettus J, Santos Caviola T, Tamborlane WV, Edelman S. The past, present, and future of basal insulins. Diabetes Metab Res Rev. 2016;32:478–496.
5. Becker RH, Dahmen R, Bergmann K, Lehmann A, Jax T, Heise T. New insulin glargine 300 Units mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units mL-1. Diabetes Care. 2015;38:637–643.
6. Bolli GB, Riddle MC, Bergenstal RM, et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people
with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015;17:386-394.

7. Riddle MC, Bolli GB, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37:2755-2762.

8. Yki-Jarvinen H, Bergenstal R, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014;37:3235-3243.

9. Riddle MC, Bolli GB, Avogaro A, et al. Assessment of hypoglycaemia during basal insulin therapy: temporal distribution and risk of events using a predefined or an expanded definition of nocturnal events. Diabetes Metab. 2018;44:333-340.

10. Terauchi Y, Koyama M, Cheng X, et al. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1). Diabetes Metab. 2016;18:366-374.

11. Terauchi Y, Riddle MC, Hirose T, et al. Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: a 12-month comparison by concomitant sulphonylurea and/or glinide use. Diabetes Obes Metab. 2018. https://doi.org/10.1111/dom.13414. [Epub ahead of print].

12. American Diabetes Association. Standards of medical Care in Diabetes – 2016. Diabetes Care. 2016;39(suppl):S1-S12.

13. Lucidi P, Porcellati F, Rossetti P, et al. Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and Detemir after 1 week of daily Administration at Bedtime in type 2 diabetic subjects: a randomized cross-over study. Diabetes Care. 2011;34:1312-1314.

14. Heller S, Mathieu C, Kapur R, Wolden ML, Zinman B. A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia. Diabet Med. 2016;33:478-487.

15. Ritzel R, Harris SB, Baron H, et al. A randomized controlled trial comparing efficacy and safety of insulin glargine 300 units/mL versus 100 units/mL in older people with type 2 diabetes: results from the SENIOR study. Diabetes Care. 2018;41:1672-1680.

16. ClinicalTrials.gov. Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications (SENIOR). 2016

**SUPPORTING INFORMATION**
Additional supporting information may be found online in the Supporting Information section at the end of the article.

**How to cite this article:** Bolli GB, Wysham C, Fisher M, et al. A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen. Diabetes Obes Metab. 2019;21:402-407. [https://doi.org/10.1111/dom.13515](https://doi.org/10.1111/dom.13515)